US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Sagiment Biosciences Inc (SGMT)
Sagiment Biosciences Inc (SGMT) Noticias

SGMT

Sagiment Biosciences (SGMT)

Sagiment Biosciences Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SGMT

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
13/06/2024	05:07	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:SGMT	Sagiment Biosciences Inc
07/06/2024	15:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SGMT	Sagiment Biosciences Inc
06/06/2024	05:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SGMT	Sagiment Biosciences Inc
15/05/2024	06:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SGMT	Sagiment Biosciences Inc
08/05/2024	15:05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:SGMT	Sagiment Biosciences Inc
25/03/2024	06:00	GlobeNewswire Inc.	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors	NASDAQ:SGMT	Sagiment Biosciences Inc
25/03/2024	05:15	GlobeNewswire Inc.	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	NASDAQ:SGMT	Sagiment Biosciences Inc
29/02/2024	07:00	GlobeNewswire Inc.	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	NASDAQ:SGMT	Sagiment Biosciences Inc
14/02/2024	17:10	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:SGMT	Sagiment Biosciences Inc
25/01/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SGMT	Sagiment Biosciences Inc
25/01/2024	19:58	GlobeNewswire Inc.	Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock	NASDAQ:SGMT	Sagiment Biosciences Inc
24/01/2024	05:08	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:SGMT	Sagiment Biosciences Inc
23/01/2024	16:45	GlobeNewswire Inc.	Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock	NASDAQ:SGMT	Sagiment Biosciences Inc
23/01/2024	16:31	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:SGMT	Sagiment Biosciences Inc
22/01/2024	06:00	GlobeNewswire Inc.	Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH	NASDAQ:SGMT	Sagiment Biosciences Inc
04/12/2023	07:00	GlobeNewswire Inc.	Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic	NASDAQ:SGMT	Sagiment Biosciences Inc
28/11/2023	07:00	GlobeNewswire Inc.	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	NASDAQ:SGMT	Sagiment Biosciences Inc
22/11/2023	07:00	GlobeNewswire Inc.	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference	NASDAQ:SGMT	Sagiment Biosciences Inc
13/11/2023	07:00	GlobeNewswire Inc.	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	NASDAQ:SGMT	Sagiment Biosciences Inc
10/11/2023	07:30	GlobeNewswire Inc.	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023	NASDAQ:SGMT	Sagiment Biosciences Inc
24/10/2023	10:00	GlobeNewswire Inc.	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023	NASDAQ:SGMT	Sagiment Biosciences Inc
18/10/2023	15:05	GlobeNewswire Inc.	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference	NASDAQ:SGMT	Sagiment Biosciences Inc
27/09/2023	15:05	GlobeNewswire Inc.	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma	NASDAQ:SGMT	Sagiment Biosciences Inc
21/08/2023	15:02	GlobeNewswire Inc.	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates	NASDAQ:SGMT	Sagiment Biosciences Inc
15/08/2023	15:04	GlobeNewswire Inc.	Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering	NASDAQ:SGMT	Sagiment Biosciences Inc
20/07/2023	15:05	GlobeNewswire Inc.	Sagimet Biosciences Announces Leadership Changes	NASDAQ:SGMT	Sagiment Biosciences Inc
13/07/2023	20:10	GlobeNewswire Inc.	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering	NASDAQ:SGMT	Sagiment Biosciences Inc
23/06/2023	01:30	GlobeNewswire Inc.	Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023	NASDAQ:SGMT	Sagiment Biosciences Inc
07/06/2023	08:00	GlobeNewswire Inc.	Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023	NASDAQ:SGMT	Sagiment Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:SGMT

1

JP Morgan Chase

Energy Select Sector SPDR

Verizon Communications

Bank of America

Deutsche Telekom (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones